A Pfizer leader who personifies our commitment to patients

Transcription

1 Pfizer Inc 235 East 42nd Street New York, NY Jeffrey B. Kindler Chief Executive Officer August 15, 2006 Dear Pfizer Colleagues, As we move forward with the work of transforming Pfizer in order to address the rapid changes taking place in the healthcare environment, I am announcing a new organizational structure that will put us in the best position to capitalize quickly on the enormous opportunities ahead of us. Karen Katen Before describing our new leadership structure, let me talk about a leader who personifies our commitment to patients: Vice Chairman Karen Katen a friend to many and a valued colleague to us all. Karen has reflected on both her professional and personal goals, and she will be leaving the company to pursue other opportunities. A Pfizer leader who personifies our commitment to patients Accordingly, others will now be assuming her operating responsibilities. At my request, however, Karen has graciously agreed to put her personal plans on hold until early next year so that she can provide advice and leadership to Pfizer and to me over the next several months in several important areas, including Pfizer Health Solutions and Pfizer Healthy Directions, as well as healthcare policy. Karen will also become the Chairman of the Pfizer Foundation. In addition, until her departure, she will be Pfizer's representative to three key business associations: the Pharmaceutical Research and Manufacturers of America (PhRMA); the U.S.-Japan Business Council; and the Healthcare Leadership Council. I know I join with all Pfizer colleagues in expressing the deepest admiration and thanks to Karen for her dedication and her many contributions to our company. Over more than three decades, Karen has played a critical role in the growth of Pfizer to world leadership in pharmaceuticals. She led the introduction of many of Pfizer s most important medicines, including breakthrough therapies for the treatment of cardiovascular disease, mental illness, diabetes and cancer, among others. But just as important, Karen reflects Pfizer s values and she has always demonstrated strong and effective leadership at the company throughout her career. Thank you, Karen, for all that you have done, and will continue to do, to sustain our progress. A Streamlined Organization Our new organizational structure builds on the strengths of our company while responding to the accelerating changes in the environment in which we operate. The creation of Pfizer Human Health marked the establishment of a single, end-to-end pharmaceuticals business spanning the entire life cycle of a product. It was an important and valuable step forward in focusing the company s strategy and resources on the priorities of our core business. But there s no question that the world around us is changing rapidly. Science is creating wholly new ways to treat disease; regulators and payers are more demanding; and patients and their families are using newly available information to take more control over their healthcare decisions. And the divestiture of Pfizer s Consumer Healthcare division gives us the opportunity to focus with even greater intensity on our core

2 business so that we can put it in the best possible position to succeed and grow. We need to align our organization to today s markets, so that we see opportunities quickly and act on them, whether that means increasing support for successful new medicines, forging partnerships with key customers, entering into copromotion and licensing agreements, investing in new technologies to add value to our core product offerings, or acquiring new products and services from outside the company. We need an integrated, leaner structure in which line management, functional experts, and a few centers of excellence work in close collaboration to advance our business objectives. Moving to a one company model eliminates unnecessary layers and helps speed decision-making. Consistent with our objective of operating as One Pfizer, we will be bringing together the previously separate divisional and Corporate organizations in finance, human resources, information technology and others as appropriate. While the specific reporting relationships within these enabling functions are not yet finalized, colleagues in these areas will have clear accountabilities both to the line leaders they support as well as to their functional leaders. Now is the right time to pursue all our opportunities as one company, so that we can: We need to align our organization to today s markets The spirit of a small company with the advantages of our unmatched scale and reach Become more agile and entrepreneurial -- embracing the spirit of a small company while exploiting the advantages of our unmatched scale and reach. Guided by the Therapeutic Area strategies we will continue to grow our portfolio of research opportunities, expand our presence in new disciplines such as genomics and biologics, and advance a wide and promising range of new therapies that represent the best of cutting-edge biomedical research from our outstanding scientists. In addition to our own research, we also have the capability to build valuable strategic alliances with the best scientists in the world, wherever in the world they may work. Build a broad, deep and diverse pool of talent. As we take on the challenges and opportunities ahead of us, we will look to develop and advance outstanding Pfizer colleagues, but we will also be willing to look outside the company for exceptional talent to meet our needs. Accelerate the development of patient support and compliance programs that will enhance the value of the medicines we offer to patients. With Chantix, for example, we re providing extensive programs beyond our medicine alone to help smokers quit their habit. Harness technology for the company s competitive advantage. Technology is critical both to improving our productivity internally and to offering innovative healthcare solutions externally, particularly in helping us deliver new solutions to physicians and patients. Listen to our customers and work in partnership with them. We will focus on products and services that encourage prevention and wellness, reduce the cost of disease and improve the quality of life. Leadership Appointments Pfizer s new Executive Leadership Team (ELT), which we are establishing today, brings together all the essential elements necessary for us to compete in this new era for healthcare. It is the senior-most leadership, management and decision-making body of the company. The ELT consists of myself and my seven direct reports: Vice Chairman David Shedlarz, who will be assuming expanded responsibilities; PGRD President John LaMattina, whose role reflects the crucial

3 importance of science to Pfizer s future; Worldwide Pharmaceuticals Operations President Ian Read, who will lead an integrated global unit; Chief Medical Officer Dr. Joe Feczko; Worldwide Talent Development and Human Resources leader Sylvia Montero; General Counsel Allen Waxman; and Worldwide Public Affairs and Policy leader Rich Bagger. Marc Robinson, President of Pfizer Consumer Healthcare, will continue to report to me until the divestiture of PCH is complete. Attached to this memo is an organization chart showing the ELT and their direct reports, as well as their biographies. What follows is more detail regarding the roles and responsibilities of these seven leaders. David Shedlarz To help drive Pfizer s transformation at this pivotal time, I have asked Pfizer s Vice Chairman, David Shedlarz -- working in partnership with me and Pfizer colleagues from all parts of the company -- to assume a number of new and important responsibilities. David s responsibilities will now consist of Pfizer Global Manufacturing (which will now include Capsugel, a world leader in supplying innovative capsules), finance, Pfizer Animal Health, worldwide strategic planning, worldwide licensing and business development, worldwide technology, business services, investor development and internal audit. The leaders of each of these areas will report to David, and David will report to me. One major focus for David will be to apply technology across the company both to improve productivity as well as to help develop new services that enhance the value of our medicines. Pfizer s Global Manufacturing is a world-class operation that gives Pfizer a significant competitive advantage under the strong leadership of Nat Ricciardi, who will report to David. Because Nat and his team have done such an outstanding job in making continuous improvement a way of life in PGM, David and I have asked him to lead a company-wide effort to develop, share and instill continuous improvement ideas, tools and best practices throughout the entire enterprise. In addition, Guido Driesen, President of Capsugel, will report to Nat. Pfizer s Animal Health business, the largest of its kind in the world, aligns naturally with our pharmaceuticals business through its extensive knowledge of medicine and its focus on finding new treatments for disease. It is an important part of Pfizer, and it will now report to David. Alan Levin will continue as Chief Financial Officer. George Henninger, Human Health Finance, will report to Alan and work with him to form the combined Pfizer Finance organization. Amal Naj, Head of Worldwide Investor Development and Hugh Donnelly, Head of Internal Audit, will continue to report to David. Greg Vahle, Head of Business Services, in addition to his current direct reports, will assume responsibilities for Global Sourcing and Human Resource Operations, with Lisa Martin and Tim Cowley, respectively, reporting to him. The selection process for the newly created positions of Worldwide Strategic Planning, Worldwide Licensing and Business Development, and Worldwide Technology will begin immediately and will extend to internal and external candidates. In the interim, Jonathan White, Human Health Information Technology/Business Strategy and Development; Chuck Williams, Corporate Information Technology; Lisa Ricciardi, Licensing; and Peter Garrambone, Business Development, will report to David. To his new role as my principal deputy, David brings strategic insight, years of experience in our industry and many important accomplishments achieved during his distinguished career at Pfizer. David has played an important role in many of the company s key strategic initiatives. He is well-known in the investment community, where he has been instrumental in building Pfizer s reputation for financial transparency and excellence in reporting. And he played a critical role in the company s recent, successful review of strategic alternatives which led to the agreement to sell Pfizer Consumer Healthcare. Beyond these tangible accomplishments, many of you know David as a Pfizer leader with a deep and abiding commitment to our mission and the ability to bring colleagues together and inspire them to work toward a common goal. I know I will turn to him for counsel many times in the days ahead, as we all work to make Pfizer an even greater company. A Pfizer leader with a deep and abiding commitment to our mission Please join me in congratulating David on his expanded responsibilities.

4 The following skilled and experienced leaders will, along with David and myself, comprise the ELT: Ian Read Worldwide Pharmaceutical Operations Ian will assume global responsibility for Worldwide Pharmaceutical Operations, which includes area and country management as well as sales and marketing. Ian has 28 years of experience with Pfizer in positions of increasing responsibility. He has done an excellent job as area president for Europe, Canada, Africa/Middle East and Latin America. In markets where governments are often the sole customer, Ian has placed a strong emphasis on the value to society of innovative medicines. The following accomplished Pfizer leaders will report directly to Ian: In the United States, Peter Brandt, currently executive vice president of U.S. Pharmaceuticals, will assume sole leadership of U.S. Pharmaceutical Operations. With 28 years in finance and line management at Pfizer, Peter brings analytical and financial skills, as well as a deep understanding of the U.S. marketplace, to his new responsibilities. Marie-Caroline Sainpy continues in her dual role as head of marketing for the U.S. and Worldwide, reporting to Peter and to Ian. Pat Kelly s leadership was instrumental in the achievements of U.S. Pharmaceuticals in recent years. Pat has made many important contributions to Pfizer throughout his career at the company, including developing marketing strategies for some of our most successful products and providing important leadership in public policy development and advocacy. Pat is looking at other career opportunities within Pfizer where he can apply his extensive knowledge of our industry as well as his leadership experience. Pedro Lichtinger, currently president of Pfizer Animal Health, will assume responsibility for pharmaceutical operations in Europe. Since taking over the leadership of Animal Health in 2000, Pedro and his team have delivered strong performance with a focus on new products, improved relationships with customers and operational efficiency, and his new role is a reflection of that performance. Naming a successor to Pedro will be an immediate priority. Pedro has over 25 years of experience in diverse markets including the United States, Latin America and Europe. Dudley Schleier, who has served in senior management positions at Pfizer for over 30 years, will continue to lead the Japan/Asia region. Dudley has held positions in sales, marketing, country and regional management during his Pfizer career. He has provided strong leadership and consistently delivered outstanding results. Andreas Fibig will continue to be in charge of Latin America and Africa/ Middle East. Andreas has nearly 30 years of pharmaceutical experience and a record of results that combines a range of skills in marketing, sales, operations, finance and developing talent. Jean-Michel Halfon will continue as head of Pfizer Canada, reporting to Ian. He had over 20 years of increasing

5 responsibilities with Pfizer in sales and marketing before being appointed to his current position in He is a strong leader, and he has implemented, among other initiatives, innovative talent planning at Pfizer Canada. John LaMattina PGRD John will continue his outstanding leadership of Pfizer s Global Research and Development, which is devoted to producing the next generation of Pfizer medicines. John will report directly to me. John has been with Pfizer almost 30 years and was named president of R&D in As we all know and as I reaffirmed at a meeting in New London in my first week on the job, science is at the heart of what we do. John has emphasized increasing Pfizer s R&D productivity, in terms of improving both candidate quality and output, which has led to the filing of a total of 18 New Drug Applications in the last five years. John s direct reports will include Martin Mackay leading Worldwide Research; Dec Doogan, who continues in his current role in Worldwide Development; and Ed Harrigan, head of Worldwide Regulatory Affairs with dual reporting to Joe Feczko (see below). Peter Corr, Senior Vice President for Science and Technology, has chosen to retire from Pfizer late this year. Peter was instrumental in strengthening our partnerships with key science and medical organizations, and he worked tirelessly to communicate the value of our industry and the importance of medical research to society. Please join me in wishing Peter well. Joe Feczko Chief Medical Officer As Pfizer s Chief Medical Officer, reporting directly to me, Joe will be responsible for all aspects of the company s medical affairs including global regulatory matters and medical policies with a particular emphasis on programs post-nda approval. He will also be responsible for all of the company s in-line products from a medical perspective. Joe s role externally will expand, as he works to enhance the company s relationships with government regulators, organized medicine and key medical opinion leaders around the world. The basis of trust with these important constituencies is Pfizer s commitment to good medicine and the highest standards of safety and efficacy and Joe will be an outstanding representative of the company with these stakeholders. Joe is a board-certified internist and infectious disease specialist with 20 years of experience at Pfizer. Pre-approval Worldwide Development, to which Joe has made many valuable contributions, will now be led by Dec Doogan. Ed Harrigan will report to John LaMattina on all matters pre-nda filing and to Joe on company relationships with regulators post-nda approval and for other policy matters. Other direct reports to Joe will be Michael Berelowitz, Worldwide Medical; John Wolleben, Safety/Risk Management; and Mike Magee, Science Advocacy. Sylvia Montero Worldwide Talent As you know, I have placed a strong emphasis on making Pfizer an even better place to work, and putting every colleague in a position to succeed. I have also stressed that we need to sustain and expand a culture of diversity and inclusion. I am pleased that these imperatives

6 Development and Human Resources will be led by Sylvia Montero, reporting directly to me. Sylvia joined Pfizer in 1978 and was promoted to senior vice president, human resources last year. As the head of Worldwide Talent Development and Human Resources, she will be responsible for the overall strategy and development of company-wide Human Resources policies, plans and practices. In addition to Sylvia s direct reports, Bob Brown, Human Health Human Resources, will also report to Sylvia and will work with her to form the combined Pfizer Human Resources organization. Allen Waxman General Counsel Allen will succeed me as Pfizer s General Counsel. The legal organization will continue to have responsibility for counseling the company on business matters and transactions, intellectual property issues, regulatory law and compliance matters, global security, litigation, corporate governance, employment law and other legal matters. In his three years with Pfizer, Allen has built a dedicated team of highly skilled professionals and has successfully managed some of the company s most significant legal issues. Rich Bagger Worldwide Public Affairs and Policy Rich will head Pfizer s Worldwide Public Affairs and Policy (previously, Corporate Affairs) division, whose name change reflects the expanded role of the function in both shaping public policy and developing new initiatives that will give Pfizer a competitive advantage in the rapidly changing policy environment. Rich will have responsibility for public policy development, government relations, communications, media, philanthropy and stakeholder advocacy. In addition to helping shape our worldwide operating environment on behalf of patients and Pfizer s mission, Rich s team will also work collaboratively with other parts of the business to ensure that we anticipate and respond quickly to changes in our environment. Rich combines advocacy for Pfizer with the ability to find common ground that enables us to advance positive policy solutions. We are implementing this new structure at a time when our business has considerable momentum. So, as we make these changes, I ask that everyone continue to stay focused on their responsibilities and on delivering results. It s important that we meet our commitments over the balance of the year and go into 2007 focused on continually improving all aspects of our company. We all know why we are here: because the mission of our company is so important. We have helped many patients live longer and healthier lives, but at the same time we know there remain more people around the world looking to us for new treatments and many cures. We now move forward as One Pfizer. I am more convinced than ever that our future is filled with opportunities. Your spirit and enthusiasm, combined with a leaner and simpler organizational structure, puts us on the path to great things in the years ahead. Sincerely,

7